Cytolytic CD4+ T Cell Isolation via Phenotypic Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining and identifying cytolytic CD4+ T cells are limited by their low frequency, difficulty in expansion, and non-specific functional activity, particularly in immune disorders treatment.
Innovation Solution
Developed methods for identifying and obtaining cytolytic CD4+ T cells by characterizing their unique markers and functions, such as undetectable Foxp3 expression, increased AKT phosphorylation, and specific cytokine production, and inducing them using immunogenic peptides with a C-(X)2-[CST] or [CST]-(X)2-C motif in the presence of IL-2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural regulatory T cells are used for controlling immune disorders, then suppressive activity is achieved, but the frequency of cells with defined specificity is very low and expansion is difficult
Solution Approach 1:
The patent segments the T cell population by identifying distinct phenotypic markers (Foxp3+, CD25+, GITR+ for natural Tregs versus Foxp3-, CD25+, GITR+, CTLA-4+ for cytolytic T cells). This segmentation allows isolation and expansion of specific cytolytic T cell subsets with defined antigen specificity, resolving the contradiction between maintaining suppressive activity and achieving sufficient cell frequency for therapy.
Solution Approach 2:
The patent applies parameter changes by using specific phenotypic markers (Foxp3 expression status, CD25, GITR, CTLA-4 levels) to distinguish and select cytolytic T cells from natural regulatory T cells. This enables enrichment of cytolytic populations that can be expanded in vitro while maintaining their cytotoxic function, thereby increasing cell frequency without compromising therapeutic efficacy.
2Reliability
If natural regulatory T cells are used, then suppressive activity is achieved, but the functional activity is non-specific
Solution Approach 1:
The patent applies local quality by confining the suppressive/cytolytic function to specific T cell populations that express particular phenotypic markers (Foxp3-, CD25+, GITR+, CTLA-4+). This localized characterization ensures that only T cells with the appropriate specificity and functional profile are selected for adoptive transfer, eliminating the non-specificity problem while preserving therapeutic activity.
Solution Approach 2:
The patent employs feedback mechanisms through phenotypic marker analysis (Foxp3, CD25, GITR, CTLA-4 expression patterns) to identify and select cytolytic T cells with defined antigen specificity. This feedback-based selection process ensures that expanded cell populations maintain the desired specific cytolytic function, resolving the contradiction between reliability and precision.
3Measurement precision
If cytolytic CD4+ T cells are identified and expanded, then specificity and efficacy are enhanced, but the complexity of identification and characterization increases
Solution Approach 1:
The patent applies preliminary action by pre-defining the phenotypic marker profile (Foxp3-, CD25+, GITR+, CTLA-4+) that characterizes cytolytic T cells before expansion. This preliminary characterization framework simplifies the identification process by providing clear selection criteria, reducing the complexity of cell sorting and validation while ensuring high specificity of the expanded population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable the isolation and expansion of cytolytic CD4+ T cells with enhanced specificity and efficacy, capable of inducing apoptosis in antigen-presenting cells and bystander T cells, making them suitable for immune disorder treatment through adoptive cell transfer.
Implementation Method 1
increased activity of the serine-threonine kinase AKT... strong phosphorylation of PI3K and of AKT... capable of inducing apoptosis in antigen-presenting cells and bystander T cells
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them.